BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Parasites are an often-overlooked threat in pet care, especially for cats, as infestations can cause serious health issues ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
The increasing demand for gene therapy and CRISPR technology increases the genome engineering.Dublin, Feb. 12, 2025 (GLOBE ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback